ArriVent BioPharma, Inc. (AVBP)
$16.46-1.61%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $767M
- Beta
- 1.35
- P/E (TTM)
- -4.10
- Short % float
- 28.38%
- Days to cover
- 11.3
- SI change
- -3.6%
- 1W
- -42.16%
- 1M
- -43.24%
- vs SPY 1W
- -42.59%
- vs SPY 1M
- -45.30%
Industry peers
FMP comparable companies · ranked by market cap
- EXELBUYExelixis, Inc.$14.8BBULLQ 10$59.02-0.07%
- ERASSELLErasca, Inc.$5.4BRECOVERYQ 4$15.46-3.56%
- IDYASELLIDEAYA Biosciences, Inc.$3.4BBEARQ 25$36.06-0.14%
- ZLABSELLZai Lab Limited$2.8BRECOVERYQ 8$24.81-1.60%
- HCMBUYHUTCHMED (China) Limited$2.4BRECOVERYQ 5$13.67-2.98%
- NUVBSELLNuvation Bio Inc.$1.7BCRISISQ 4$4.95-2.00%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$12.03-1.50%
- TYRASELLTyra Biosciences, Inc.$1.2BCRISISQ 5$19.97-1.71%
- PBYIBUYPuma Biotechnology, Inc.$507MBULLQ 13$9.97+0.00%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AVBP?
- LOPJLB’s latest quantitative signal on ArriVent BioPharma, Inc. (AVBP) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AVBP in?
- ArriVent BioPharma, Inc. (AVBP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ArriVent BioPharma, Inc. (AVBP) do?
- ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The companyâs lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mu…